AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21488754 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 g of English walnuts per day for 30 days
Number of subjects: 36
Study 21488754 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 g of black walnuts per day for 30 days
Number of subjects: 36
Study 19716560 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotics
Number of subjects: 1829
Study 19716560 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1829
Study 17671215 — intervention group
Group type: EXPERIMENTAL
Intervention: zoledronate + IL-2
Number of subjects: 18
Study 17671215 — intervention group
Group type: COMPARATOR
Intervention: zoledronate
Number of subjects: 18
Study 15923688 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition education intervention delivered monthly by trained counsellors
Number of subjects: 138
Study 15923688 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition education intervention
Number of subjects: 138
Study 15923688 — intervention group
Group type: COMPARATOR
Intervention: Non-intervention group (control)
Number of subjects: 138
Study 11973440 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral 17beta-estradiol 1 mg daily continuously combined with dydrogesterone 2.5 mg daily
Number of subjects: 508
Study 11973440 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral 17beta-estradiol 1 mg daily continuously combined with dydrogesterone 5 mg daily
Number of subjects: 508
Study 11973440 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral 17beta-estradiol 1 mg daily continuously combined with dydrogesterone 10 mg daily
Number of subjects: 508
Study 11973440 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral 17beta-estradiol 1 mg daily continuously combined with dydrogesterone 20 mg daily
Number of subjects: 508
Study 11973440 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral 17beta-estradiol 1 mg daily continuously combined with dydrogesterone 2.5 to 20 mg daily
Number of subjects: 508
Study 9819446 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with interferon alfa-2b and ribavirin (1000 or 1200 mg orally per day) for 24 weeks
Number of subjects: 912
Study 9819446 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with interferon alfa-2b and ribavirin (1000 or 1200 mg orally per day) for 48 weeks
Number of subjects: 912
Study 9819446 — intervention group
Group type: COMPARATOR
Intervention: Interferon alfa-2b alone for 24 weeks
Number of subjects: 912
Study 9819446 — intervention group
Group type: COMPARATOR
Intervention: Interferon alfa-2b alone for 48 weeks
Number of subjects: 912
Study 9819446 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy for 24 weeks
Number of subjects: 912
Study 9819446 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy for 48 weeks
Number of subjects: 912
Study 9819446 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy
Number of subjects: 912
Study 7657738 — intervention group
Group type: EXPERIMENTAL
Intervention: Pergonal
Number of subjects: 20
Study 7657738 — intervention group
Group type: COMPARATOR
Intervention: Humegon
Number of subjects: 20
Study 7657738 — intervention group
Group type: EXPERIMENTAL
Intervention: Pergonal batches
Number of subjects: 20
Study 2711343 — intervention group
Group type: EXPERIMENTAL
Intervention: p(60) + Be-neutrons
Number of subjects: 67
Study 2711343 — intervention group
Group type: COMPARATOR
Intervention: photons
Number of subjects: 67
Study 8961 — intervention group
Group type: EXPERIMENTAL
Intervention: Single intracarotid injection of phenoxybenzamine
Number of subjects: 100
Study 8961 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged treatment with propranolol
Number of subjects: 100
Study 29987740 — intervention group
Group type: EXPERIMENTAL
Intervention: Future-oriented text messages
Number of subjects: 270
Study 29987740 — intervention group
Group type: COMPARATOR
Intervention: Short-term text messages
Number of subjects: 270
Study 28545564 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil 1.0 μg ml‐1 plus dexmedetomidine 4 μg ml‐1 (Group SD)
Number of subjects: 60
Study 28545564 — intervention group
Group type: COMPARATOR
Intervention: Sufentanil 1.0 μg ml‐1 (Group S)
Number of subjects: 60
Study 25213114 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behaviour therapy-based programme
Number of subjects: 147
Study 25213114 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 147
Study 24376277 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral support sessions plus 7 weeks of bupropion therapy (BSS+)
Number of subjects: 1955
Study 24376277 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral support sessions (BSS)
Number of subjects: 1955
Study 24376277 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 1955
Study 21566568 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin (12.5 mg kg(‐1) per day)
Number of subjects: 75
Study 21566568 — intervention group
Group type: EXPERIMENTAL
Intervention: UDCA (5 mg kg(‐1) every 6 h)
Number of subjects: 75
Study 21566568 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study 19687339 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise intervention (aerobic and strength training, 2.5 hours/week for 1 year)
Number of subjects: 189
Study 19687339 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise intervention (for women who lost more than 2% body fat)
Number of subjects: 189
Study 19687339 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise intervention (for women who lost body fat)
Number of subjects: 189
Study 19687339 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exercise)
Number of subjects: 189
Study 19687339 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise intervention
Number of subjects: 189
Study 17449575 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium hyaluronate (NaH, 300 mg)
Number of subjects: 16
Study 17449575 — intervention group
Group type: EXPERIMENTAL
Intervention: Chondroitin sulfate (CS, 360 mg)
Number of subjects: 16
Study 17449575 — intervention group
Group type: COMPARATOR
Intervention: Control (SSM without GAG)
Number of subjects: 16
Study 16351336 — intervention group
Group type: EXPERIMENTAL
Intervention: New Hope program to increase parent employment and reduce poverty
Number of subjects: 0
Study 16351336 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 16351336 — intervention group
Group type: EXPERIMENTAL
Intervention: New Hope program
Number of subjects: 0
Study 12154422 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactated Ringer's solution (LR)
Number of subjects: 90
Study 12154422 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% hetastarch in normal saline (HS-NS)
Number of subjects: 90
Study 12154422 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% hetastarch in balanced-saline vehicle (HS-BS)
Number of subjects: 90
Study 10604523 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin converting enzyme (ACE) inhibitors
Number of subjects: 116
Study 10604523 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium antagonists
Number of subjects: 116
Study 10604523 — intervention group
Group type: COMPARATOR
Intervention: Hypertensive group
Number of subjects: 116
Study 10604523 — intervention group
Group type: COMPARATOR
Intervention: Normotensive group
Number of subjects: 116
Study 10604523 — intervention group
Group type: COMPARATOR
Intervention: Hypotensive group
Number of subjects: 116
Study 7605180 — intervention group
Group type: EXPERIMENTAL
Intervention: Underarm braces
Number of subjects: 50
Study 7605180 — intervention group
Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 50
Study 2213635 — intervention group
Group type: EXPERIMENTAL
Intervention: Unlimited sleep (11:00 p.m.‐8:00 a.m.)
Number of subjects: 30
Study 2213635 — intervention group
Group type: EXPERIMENTAL
Intervention: Early partial sleep (11:00 p.m.‐3:00 a.m.)
Number of subjects: 30
Study 2213635 — intervention group
Group type: EXPERIMENTAL
Intervention: Late partial sleep (4:00 a.m.‐8:00 a.m.)
Number of subjects: 30
Study 448008 — intervention group
Group type: EXPERIMENTAL
Intervention: Buasch and Lomb Soflens contact lenses
Number of subjects: 24
Study 448008 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocurve II contact lenses
Number of subjects: 24
Study 448008 — intervention group
Group type: EXPERIMENTAL
Intervention: AOSoftTM hydrophillic contact lenses
Number of subjects: 24
Study 30063723 — intervention group
Group type: EXPERIMENTAL
Intervention: High VEGF-A protein expression
Number of subjects: 585
Study 30063723 — intervention group
Group type: EXPERIMENTAL
Intervention: High VEGFR1 expression
Number of subjects: 585
Study 30063723 — intervention group
Group type: EXPERIMENTAL
Intervention: High VEGFR3 expression
Number of subjects: 585
Study 30063723 — intervention group
Group type: EXPERIMENTAL
Intervention: High VEGF-C protein expression
Number of subjects: 585
Study 27561420 — intervention group
Group type: EXPERIMENTAL
Intervention: Optiscope™
Number of subjects: 168
Study 27561420 — intervention group
Group type: COMPARATOR
Intervention: Lightwand
Number of subjects: 168
Study 24938324 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol at 80 mg/day plus HFA-BDP at 100 μg/day
Number of subjects: 16
Study 24938324 — intervention group
Group type: COMPARATOR
Intervention: HFA-BDP at 400 μg/day
Number of subjects: 16
Study 22874535 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium nitrate (614-mg nitrate)
Number of subjects: 10
Study 22874535 — intervention group
Group type: COMPARATOR
Intervention: Placebo (nitrate-free)
Number of subjects: 10
Study 22874535 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrate
Number of subjects: 10
Study 22874535 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 20368057 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified expansive open‐door cervical laminoplasty
Number of subjects: 49
Study 20368057 — intervention group
Group type: COMPARATOR
Intervention: Conventional C3‐C7 cervical expansive open‐door laminoplasty
Number of subjects: 49
Study 19337557 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 PUFAs plus rosuvastatin 10 mg
Number of subjects: 30
Study 19337557 — intervention group
Group type: COMPARATOR
Intervention: Rosuvastatin 10 mg alone
Number of subjects: 30
Study 19337557 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 PUFAs added to rosuvastatin 10 mg
Number of subjects: 30
Study 16250069 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine (2.5 to 7.5 mg/d)
Number of subjects: 268
Study 16250069 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 268
Study 16250069 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine (2.5 to 7.5 mg/d) in patients with MMSE scores of 14-18 (n = 35)
Number of subjects: 268
Study 16250069 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine (2.5 to 7.5 mg/d) in patients with MMSE scores of 23-26 (n = 78)
Number of subjects: 268
Study 12781159 — intervention group
Group type: EXPERIMENTAL
Intervention: High-protein pre-load (29% protein, approximately 3MJ, 0.5 kg)
Number of subjects: 16
Study 12781159 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat pre-load (40% fat, approximately 3MJ, 0.5 kg)
Number of subjects: 16
Study 12781159 — intervention group
Group type: EXPERIMENTAL
Intervention: High-carbohydrate pre-load (60% carbohydrate, approximately 3MJ, 0.5 kg)
Number of subjects: 16
Study 12781159 — intervention group
Group type: COMPARATOR
Intervention: No pre-load
Number of subjects: 16
Study 10229732 — intervention group
Group type: EXPERIMENTAL
Intervention: GV150526 (800 mg loading dose followed by 400 mg BID maintenance)
Number of subjects: 66
Study 10229732 — intervention group
Group type: EXPERIMENTAL
Intervention: GV150526 (200 mg BID maintenance)
Number of subjects: 66
Study 10229732 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study 8916624 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Therapy (CT)
Number of subjects: 0
Study 8916624 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpersonal Therapy (IPT)
Number of subjects: 0
Study 8916624 — intervention group
Group type: COMPARATOR
Intervention: Cognitive Therapy (CT) and Interpersonal Therapy (IPT)
Number of subjects: 0
Study 1873610 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocolloid dressing
Number of subjects: 65
Study 1873610 — intervention group
Group type: COMPARATOR
Intervention: Alginate dressing
Number of subjects: 65
Study 6871083 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg almitrine
Number of subjects: 12
Study 6871083 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg almitrine
Number of subjects: 12
Study 6871083 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 29347888 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive‐behavioral therapy (CBT)
Number of subjects: 0
Study 29347888 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpersonal psychotherapy (IPT)
Number of subjects: 0
Study 30115121 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate (200 mg/day)
Number of subjects: 180
Study 30115121 — intervention group
Group type: COMPARATOR
Intervention: Naltrexone (50 mg/day)
Number of subjects: 180
Study 27181886 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency jet ventilation via Wei jet nasal airway (Group A)
Number of subjects: 28
Study 27181886 — intervention group
Group type: COMPARATOR
Intervention: Controlled ventilation with improved laryngeal mask airway (Group B)
Number of subjects: 28
Study 24957863 — intervention group
Group type: EXPERIMENTAL
Intervention: Mosapride 5 mg thrice daily plus Omeprazole 10 mg once daily (GO group)
Number of subjects: 60
Study 24957863 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole alone (O group)
Number of subjects: 60
Study 24957863 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-erosive reflux disease (NERD) patients
Number of subjects: 60
Study 24957863 — intervention group
Group type: EXPERIMENTAL
Intervention: Erosive GERD patients
Number of subjects: 60
Study 22264278 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary debulking surgery (PDS) without additional diagnostic laparoscopy
Number of subjects: 200
Study 22264278 — intervention group
Group type: COMPARATOR
Intervention: Primary debulking surgery (PDS) following additional diagnostic laparoscopy
Number of subjects: 200
Study 19174703 — intervention group
Group type: EXPERIMENTAL
Intervention: American phase 3 diet for 1 month
Number of subjects: 59
Study 19174703 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet plus placebo for 1 month
Number of subjects: 59
Study 19174703 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemfibrozil (600 mg twice a day) plus American phase 3 diet for 2 months
Number of subjects: 59
Study 19174703 — intervention group
Group type: COMPARATOR
Intervention: Regular diet
Number of subjects: 59
Study 17438705 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental treatment (chemotherapy)
Number of subjects: 29
Study 15975358 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin and clopidogrel therapy with intraoperative aprotinin
Number of subjects: 50
Study 15975358 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 5 days before surgery and placebo infusions intraoperatively
Number of subjects: 50
Study 12034155 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary artery pressure
Number of subjects: 201
Study 12034155 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary capillary wedge pressure
Number of subjects: 201
Study 12034155 — intervention group
Group type: EXPERIMENTAL
Intervention: Yale Dyspnea-Fatigue Index (YDFI) score
Number of subjects: 201
Study 12034155 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-min walk test
Number of subjects: 201
Study 9821454 — intervention group
Group type: EXPERIMENTAL
Intervention: Three times weekly ECT
Number of subjects: 0
Study 9821454 — intervention group
Group type: COMPARATOR
Intervention: Once weekly ECT
Number of subjects: 0
Study 9821454 — intervention group
Group type: EXPERIMENTAL
Intervention: High stimulus dose with once weekly ECT
Number of subjects: 0
Study 7714075 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg melatonin (1 mg at 0800, 1000, and 1200 h)
Number of subjects: 16
Study 7714075 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 7714075 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg melatonin
Number of subjects: 16
Study 2845199 — intervention group
Group type: EXPERIMENTAL
Intervention: Deferoxamine (30 mg/kg IV before and after bypass, 250 mg/L in cardioplegic solution)
Number of subjects: 24
Study 2845199 — intervention group
Group type: COMPARATOR
Intervention: Control (no deferoxamine)
Number of subjects: 24
Study 2845199 — intervention group
Group type: COMPARATOR
Intervention: Deferoxamine and Control
Number of subjects: 24
Study 31621901 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention (INT) - Geriatric Acute and Post-Acute Fall Prevention Intervention (GAPcare) including medication therapy management by a pharmacist and fall risk assessment by a physical therapist.
Number of subjects: 110
Study 31621901 — intervention group
Group type: COMPARATOR
Intervention: Control (UC) - Usual care (no specific intervention details provided).
Number of subjects: 110
Study 31337525 — intervention group
Group type: EXPERIMENTAL
Intervention: Catheter ablation (CA) with anticoagulant therapy using edoxaban
Number of subjects: 250
Study 31337525 — intervention group
Group type: COMPARATOR
Intervention: Standard medication
Number of subjects: 250
Study 28991711 — intervention group
Group type: EXPERIMENTAL
Intervention: Tremor's glove (EMS)
Number of subjects: 30
Study 28991711 — intervention group
Group type: COMPARATOR
Intervention: Sham glove
Number of subjects: 30
Study 26538411 — intervention group
Group type: EXPERIMENTAL
Intervention: Pursed-lips breathing during TGlittre test
Number of subjects: 25
Study 26538411 — intervention group
Group type: EXPERIMENTAL
Intervention: Pursed-lips breathing during 6MWT
Number of subjects: 25
Study 26538411 — intervention group
Group type: COMPARATOR
Intervention: Non-Pursed-lips breathing during 6MWT
Number of subjects: 25
Study 26538411 — intervention group
Group type: COMPARATOR
Intervention: Non-Pursed-lips breathing during TGlittre test
Number of subjects: 25
Study 23169292 — intervention group
Group type: EXPERIMENTAL
Intervention: gemcitabine/erlotinib followed by capecitabine
Number of subjects: 208
Study 23169292 — intervention group
Group type: COMPARATOR
Intervention: capecitabine/erlotinib followed by gemcitabine
Number of subjects: 208
Study 23169292 — intervention group
Group type: EXPERIMENTAL
Intervention: PTEN loss
Number of subjects: 208
Study 23169292 — intervention group
Group type: EXPERIMENTAL
Intervention: KRAS wild-type
Number of subjects: 208
Study 23169292 — intervention group
Group type: EXPERIMENTAL
Intervention: EGFR overexpression
Number of subjects: 208
Study 23169292 — intervention group
Group type: EXPERIMENTAL
Intervention: EGFR gene amplification
Number of subjects: 208
Study 23169292 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin rash occurrence
Number of subjects: 208
Study 16937848 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam plus Ketamine
Number of subjects: 120
Study 16937848 — intervention group
Group type: COMPARATOR
Intervention: Midazolam
Number of subjects: 120
Study 16937848 — intervention group
Group type: COMPARATOR
Intervention: Ketamine
Number of subjects: 120
Study 16937848 — intervention group
Group type: COMPARATOR
Intervention: Zolpidem
Number of subjects: 120
Study 16937848 — intervention group
Group type: COMPARATOR
Intervention: Midazolam plus Tramadol
Number of subjects: 120
Study 16937848 — intervention group
Group type: COMPARATOR
Intervention: Zolpidem plus Tramadol
Number of subjects: 120
Study 14518608 — intervention group
Group type: EXPERIMENTAL
Intervention: L-arginine (8 g p.o. two times daily) for 14 days
Number of subjects: 12
Study 14518608 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 14 days
Number of subjects: 12
Study 14518608 — intervention group
Group type: EXPERIMENTAL
Intervention: L-arginine (8 g p.o. two times daily)
Number of subjects: 12
Study 14518608 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 14518608 — intervention group
Group type: EXPERIMENTAL
Intervention: L-arginine supplementation
Number of subjects: 12
Study 14518608 — intervention group
Group type: COMPARATOR
Intervention: Baseline ADMA levels
Number of subjects: 12
Study 14518608 — intervention group
Group type: COMPARATOR
Intervention: L-arginine and placebo
Number of subjects: 12
Study 10830415 — intervention group
Group type: EXPERIMENTAL
Intervention: tolcapone (50 mg, 200 mg, or 400 mg three times a day)
Number of subjects: 46
Study 10830415 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 46
Study 9014744 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous clodronate (1800 mg) combined with MivP chemotherapy
Number of subjects: 211
Study 9014744 — intervention group
Group type: COMPARATOR
Intervention: MivP chemotherapy alone
Number of subjects: 211
Study 9014744 — intervention group
Group type: COMPARATOR
Intervention: Lower doses of intravenous clodronate combined with MivP
Number of subjects: 211
Study 1502991 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery based on prism adapted angle in 31 prism responders
Number of subjects: 77
Study 1502991 — intervention group
Group type: COMPARATOR
Intervention: Surgery for initially measured angle in 32 prism responders
Number of subjects: 77
Study 1502991 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery for preoperative measured angle in 14 non-responders
Number of subjects: 77
Study 6507825 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine 1.2 mg
Number of subjects: 8
Study 6507825 — intervention group
Group type: COMPARATOR
Intervention: Glycopyrronium 0.6 mg
Number of subjects: 8
Study 31993783 — intervention group
Group type: EXPERIMENTAL
Intervention: Palmitoylethanolamide (PEA)
Number of subjects: 68
Study 31993783 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study 30342697 — intervention group
Group type: EXPERIMENTAL
Intervention: Once weekly dressing changes with negative pressure wound therapy (NPWT)
Number of subjects: 44
Study 30342697 — intervention group
Group type: COMPARATOR
Intervention: Thrice weekly dressing changes with negative pressure wound therapy (NPWT)
Number of subjects: 44
Study 28007665 — intervention group
Group type: EXPERIMENTAL
Intervention: Daclizumab 0.3 mg/kg
Number of subjects: 210
Study 28007665 — intervention group
Group type: EXPERIMENTAL
Intervention: Daclizumab 1.2 mg/kg
Number of subjects: 210